Senolytic treatment to rescue hallmarks of senescence in lymph node fibroblasts from patients with rheumatoid arthritis: Implications for premature aging and potential therapeutic intervention in early rheumatoid arthritis.

T A de Jong, J F Semmelink, J W Bolt, C Grasso, R A Hoebe, P M Krawczyk, L G M van Baarsen

Amsterdam UMC location, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Laboratory for Experimental Immunology, Amsterdam, The Netherlands.Amsterdam UMC location, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Laboratory for Experimental Immunology, Amsterdam, The Netherlands. · pubmed

Paper

Abstract

Cellular senescence, a state of proliferation arrest, is implicated in the pathogenesis of age-related diseases such as rheumatoid arthritis (RA). The pathogenesis of RA, characterized by immune dysregulation and systemic autoimmunity preceding clinical onset of disease, may involve early accumulation of senescent lymph node (LN) fibroblasts driving immune tolerance breakdown. This study aims to explore the hallmarks of senescence in LN fibroblasts during the earliest phases of RA and evaluate the effects of dasatinib.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that senolytic treatment can rescue hallmarks of senescence in lymph node fibroblasts from patients with rheumatoid arthritis. This research is relevant as it addresses the underlying mechanisms of cellular senescence, which is a key factor in aging and age-related diseases, potentially offering therapeutic interventions that target the root causes of premature aging in the context of rheumatoid arthritis.

Author of this paper? Send a correction.